New scientific insights into schizophrenia are pointing toward new drugs that offer hope for millions of individuals with the disease — the most serious form of mental illness, according to an article scheduled for the Sept. 15 issue of Chemical & Engineering News, ACS' weekly newsmagazine.

Researchers from UQ's Queensland Brain Institute are set to conduct a world-first trial into the link between prenatal vitamin D levels and schizophrenia prevalence.

Throughout the world, scientists are attempting to recognize and treat schizophrenic disorders at an earlier stage.

People with schizophrenia have an increased number of unusual chromosomal changes, particularly structural changes that have the potential to alter the function of the genes. These results were published today in the scientific journal Nature.

Researchers have discovered new genes linked to schizophrenia, it has been revealed.

Schizophrenia is a disease that strikes an average of 4000 Belgians every year. The causes of this psychiatric disorder are not yet clear.

Biological Psychiatry is particularly proud to announce the publication of an issue dedicated to the product of the National Institute of Mental Health (NIMH) Cognitive Neuroscience Approaches to the Treatment of Impaired Cognition in Schizophrenia, or CNTRICS, initiative.

A protein found in immune cells may be a reliable marker for schizophrenia risk, report researchers in a new proteomics study appearing in the July issue of Molecular and Cellular proteomics.

Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Some schizophrenia patients become less prone to violence when taking medication, but those with a history of childhood conduct problems continue to pose a higher risk even with treatment, according to a new study by researchers at Duke University Medical Center.

Researchers at Columbia University Medical Center have illuminated a window into how abnormalities in microRNAs, a family of molecules that regulate expression of numerous genes, may contribute to the behavioral and neuronal deficits associated with schizophrenia and possibly other brain disorders.

Neuroscientists at Johns Hopkins have discovered that mice lacking an enzyme that contributes to Alzheimer disease exhibit a number of schizophrenia-like behaviors. The finding raises the possibility that this enzyme may participate in the development of schizophrenia and related psychiatric disorders and therefore may provide a new target for developing therapies.